These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prolongation of heterotopic cardiac allografts in rats by cyclosporin A.
    Author: Kawahara K, Sutherland DE, Rynasiewicz JJ, Najarian JS.
    Journal: Surgery; 1980 Oct; 88(4):594-600. PubMed ID: 6999652.
    Abstract:
    Cyclosporin A (CsA), an investigational immunosuppressive drug, was tested for its ability to prevent rejection of heterotopic rat heart allografts transplanted across a major histocompatibility barrier (ACI to Lewis). The relative efficacy of CsA was compared to a combination of azathioprine and prednisolone. Various dose-schedule combinations of CsA as a single drug were evaluated in regard to duration of grafts beating, recipient mortality rate, and histology of long-term functioning grafts. A daily dose of CsA of 10 mg/kg prevented rejection, but was associated with a 40% recipient mortality rate from infection. CsA in 5 mg/kg/day doses resulted in long-term graft function (> 100 days), but histological examination of these grafts showed mild rejection. A dose-schedule of CsA in 10 mg/kg/day for 7 to 35 days followed by a reduction to 5 mg/kg/day prolonged the survival rate of all grafts to longer than 100 days; no rats died from this treatment and there was no evidence of rejection on graft histology. In contrast, a combination of 4 mg/kg/day azathioprine and 4 mg/kg/day prednisolone did not prolong graft survival rates. Azathioprine in 30 mg/kg and prednisolone in 12 mg/kg prolonged allograft survival (50 to 60 days), but was associated with significant recipient morbidity (> 25% weight loss) and histological evidence of acute and chronic rejection. A nontoxic dose of CsA is superior to a combination of azathioprine and prednisolone in preventing the rejection of heterotopic rat heart allografts. The therapeutic index of cyclosporin A in rats can be increased by using a tapering dose schedule, as opposed to a fixed dose schedule. CsA has good potential for clinical application to organ transplantation.
    [Abstract] [Full Text] [Related] [New Search]